Annals of neurology, 2021-12, Vol.90 (6), p.865-873
2021
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Advances in Treatment of Progressive Multifocal Leukoencephalopathy
- Ist Teil von
- Annals of neurology, 2021-12, Vol.90 (6), p.865-873
- Ort / Verlag
- Hoboken, USA: John Wiley & Sons, Inc
- Erscheinungsjahr
- 2021
- Quelle
- Wiley-Blackwell Journals
- Beschreibungen/Notizen
- Progressive multifocal encephalopathy (PML) is a severe demyelinating disease of the central nervous system (CNS) caused by JC virus (JCV), which occurs in immunocompromised individuals. Management of PML relies on restoration of immunity within the CNS. However, when this restoration cannot be readily achieved, PML has a grim prognosis. Innovative strategies have shown promise in promoting anti‐JCV immune responses, and include T‐cell adoptive transfer or immune checkpoint inhibitor therapies. Conversely, management of immune reconstitution inflammatory syndrome, particularly in iatrogenic PML, remains a major challenge. In this paper, we review recent development in the treatment of PML. ANN NEUROL 2021;90:865–873
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0364-5134eISSN: 1531-8249DOI: 10.1002/ana.26198Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9291129
- Format
- –
- Schlagworte
- Adoptive transfer, Adoptive Transfer - methods, Central nervous system, Demyelinating diseases, Demyelination, Encephalitis, Encephalopathy, Health services, Humans, Immune checkpoint inhibitors, Immune Checkpoint Inhibitors - therapeutic use, Immune reconstitution, Immune response, Inflammation, Leukoencephalopathy, Leukoencephalopathy, Progressive Multifocal - drug therapy, Leukoencephalopathy, Progressive Multifocal - therapy, Prognosis, Progressive multifocal leukoencephalopathy, Restoration, Review, Treatment Outcome, Viral infections, Viruses